The series uses the book Mitochondria and the Future of Medicine, by Lee Know, a former naturopathic doctor in Canada, as a starting point, and includes insights from ME/CFS/FM practitioners
Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses
In summary, recent CV outcomes trials with GLP-1RAs have shown promising benefits in CV care of T2D patients, and GLP-1RAs have been accordingly listed as a second line therapy in T2D patients with established atherosclerotic CV disease, alongside SGLT2 inhibitors [5, 6]
You may also receive guidance on your starting dose and how the medication will be gradually adjusted over time